跳转至内容
Merck
所有图片(1)

主要文件

查看所有文档

P-011

Supelco

(+)-丙氧芬 溶液

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C22H29NO2
CAS号:
469-62-5
分子量:
339.47
分類程式碼代碼:
41116107
PubChem物質ID:
329820017
NACRES:
NA.24

等級

certified reference material

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商／商標名

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

濃度

1.0 mg/mL in acetonitrile

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

forensics and toxicology

形式

single component solution

儲存溫度

2-8°C

SMILES 字串

CCC(=O)O[C@@](Cc1ccccc1)([C@H](C)CN(C)C)c2ccccc2

InChI

1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1

InChI 密鑰

XLMALTXPSGQGBX-GCJKJVERSA-N

基因資訊

human ... OPRM1(4988)

一般說明

经认证的Snap-N-Spike®溶液标准品，适用于疼痛处方监测、临床毒理学、尿液药物测试或法医分析中通过GC/MS或LC/MS进行丙氧芬测试的方法。丙氧芬，也称为右丙氧芬，是一种阿片类镇痛药，旨在治疗轻度疼痛。右丙氧芬与扑热息痛或阿司匹林合用时，以商品名销售，包括Darvocet-N®和Darvon®。

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Darvocet-N is a registered trademark of AAIPharma LLC
Darvon is a registered trademark of Xanodyne Pharmaceuticals, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

相關產品

产品编号
说明
价格

N-904

(±)-Norpropoxyphene-d5 maleate solution, 100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

N-913

(+)-Norpropoxyphene maleate solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

N-919

(±)-Norpropoxyphene-d5 maleate solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

P-901

(±)-Propoxyphene-D5 solution, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

P-904

(±)-Propoxyphene-D5 solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

P-914

(±)-Propoxyphene-D11 solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

象形圖

FlameExclamation mark
GHS02,GHS07

訊號詞

Danger

危險分類

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

儲存類別代碼

3 - Flammable liquids

水污染物質分類（WGK）

WGK 2

閃點（°F）

35.6 °F - closed cup

閃點（°C）

2 °C - closed cup

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系 客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Suicides involving co-proxamol fell dramatically after withdrawal in UK.
Zosia Kmietowicz
BMJ (Clinical research ed.), 344, e3255-e3255 (2012-05-11)
Margareeta Häkkinen et al.
Forensic science international, 222(1-3), 327-331 (2012-08-14)
There is a rising trend of fatal poisonings due to medicinal opioids in several countries. The present study evaluates the drug and alcohol findings as well as the cause and manner of death in opioid-related post-mortem cases in Finland from
W Stephen Waring et al.
Clinical toxicology (Philadelphia, Pa.), 49(6), 452-456 (2011-08-10)
The Medicines and Healthcare products Regulatory Authority (MHRA) is the government body with responsibility for regulating new and existing medicines and medical devices in the United Kingdom. The Yellow Card scheme is a well-established pharmacovigilance system that collects voluntary reports
Robert B Raffa et al.
Expert opinion on pharmacotherapy, 13(10), 1397-1409 (2012-05-10)
d-Propoxyphene, which was previously available in many single-agent and combination products, was recently voluntarily withdrawn from the US market following an FDA recommendation based partly on the concern that the risk associated with QT prolongation exceeded the clinical benefit of
Yatan Pal Singh Balhara et al.
Journal of opioid management, 8(1), 45-49 (2012-04-07)
In view of increasing safety concerns, there is a need to assess benefits of use of dextropropoxyphene as opioid substitution treatment, if any. This study aims at urinalysis-based comparative evaluation of pattern of use of dextropropoxyphene and buprenorphine among opioid-dependent
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门